The Federal Trade Commission (FTC) is targeting patent listings for 20 branded drugs, including Novo Nordisk’s Ozempic and Victoza, to accelerate competition from generic drugs. This move is part of broader efforts to address concerns over 'junk' patents that delay generic market entry. Concurrently, Denmark is implementing restrictions on the prescription of GLP-1 drugs like Novo Nordisk’s Ozempic for type 2 diabetes, prioritizing cheaper alternatives due to the significant financial impact on its healthcare system. In 2023, Denmark spent $200 million on Ozempic, accounting for 8% of all medicine costs, a figure that has doubled from the previous year.
The development of semaglutide, the key ingredient in wight loss medicines, has transformed their maker, Novo Nordisk, into Europe’s most valuable company, with profound implications for its home country of #Denmark. https://t.co/WmewtFSxZP
Ozempic may soon be to weight-loss drugs what Advil is to ibuprofen – an expensive alternative to the generic brand. That’s if the FTC has its way. https://t.co/4uDYUzJBXi
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes https://t.co/XtlLu8JuwQ https://t.co/SQY9RD4gQq
. @FTC sends more warnings to #pharma companies over 'junk' patents to protect drugs from generic competition, including @NovoNordisk's big-selling diabetes therapy Ozempic. https://t.co/t74ZbXrEpR https://t.co/ResAARnDD5
Denmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk's Ozempic, the Danish Medicines Agency said on Wednesday. https://t.co/bYURGllpPd https://t.co/bYURGllpPd
"The rising popularity of Novo’s diabetes drug has led to a massive bill for Denmark’s public health care system. Danish authorities spent $200 million on Ozempic in 2023 — 8% of all medicine costs, and twice as much as the previous year." https://t.co/6teRAabW5i
Blockbusters including Novo Nordisk’s Ozempic and Victoza are among 20 branded drugs the FTC is targeting in an effort to accelerate generic competition. https://t.co/SJRNKyKCIa
🇺🇸 How supplement stores are trying to tap Into the Ozempic boom https://t.co/cfGbMWkxu4
*FTC Targets Patent Listings on Ozempic, Other Drugs, Sources Say -- WSJ *FTC Sees Drugmakers' Patent Efforts as Attempt to Delay Competition From Generic Drugs, Sources Say -- WSJ Lina Khan will not rest until she is centrally planning the entire global economy